Citations

Clear

2 citation(s) found for "Singh, Pawan".

PSMA PET/CT for Radiation Planning and Response Assessment in Intracranial High-Grade Gliomas
Upadhyay, Rituraj , Kumar, Pavnesh , Tang, Bingfeng , Bello‐Pardo, Erika, Mohtashami, Hamid, Singh, Pawan, Giglio, Pierre , Wu, Kyle , Elder, J Brad, Beyer, Sasha, Singh, Raj, Raval, Raju R. , Thomas, Evan , Zhang, Chi , Ivanidze, Jana, Yadav, Divya , Mohtashami, Hamid, Ivanidze, Jana , Palmer, Joshua D. , Giglio, Pierre , Wu, Kyle C , Ivanidze, Jana , Palmer, Joshua D

Mayo Clinic

Neuro-Oncology Advances | August 14, 2026 | Volume: No volume available | Issue: No issue available | Pages: No page available

10.1093/noajnl/vdag217 | PMID 42828195 Get It

Lay Summary Glioblastoma is an aggressive brain cancer, and it can be difficult to tell whether changes seen on scans after radiation treatment represent tumor growth or treatment-related effects. The authors of this study wanted to evaluate whether a specialized imaging test called PSMA PET could help define tumor boundaries for radiation planning and distinguish tumor progression from treatment-related changes. To do this, they performed PSMA PET scans in 27 patients with high-grade gliomas, including patients undergoing radiation planning and patients being evaluated for possible tumor recurrence. They found that tumors showed higher PSMA PET signal than surrounding tissue, that PSMA PET sometimes identified tumor beyond what was visible on standard MRI, and that it correctly distinguished tumor progression from treatment-related changes in most patients.
Immune checkpoint inhibitors in metastatic NSCLC: challenges and future directions (CME article)
Parikh, Kaushal , Sridhar, Arthi , Singh, Pawan Kumar

Mayo Clinic

International Journal of Cancer Care and Delivery | March 14, 2023 | Volume: 3 | Issue: 1 | Pages: No page available

10.53876/001c.72631 Get It

The treatment metastatic non-small cell lung cancer (NSCLC) is largely influenced by the incorporation of immune checkpoint inhibitors (ICI) in the frontline setting. There are several ICI approved for the management of NSCLC based on the PD-L1 expression of the tumors. PD-L1 is a controversial biomarker with various inconsistencies in expression owing to temporal and spatial heterogeneity. Tumor mutational burden is another much studied biomarker associated with its own challenges and questionable concordance with tumor PD-L1 expression. In this article, we aim to discuss the challenges associated with the existing biomarkers, highlighting the need for emerging biomarkers that can help with decision making in the management of this there where several therapeutic options exist. There are emerging “me too” PD-1/PD-L1 drugs which may serve its purpose in many counties where there is limited access to current approved ICIs. What is increasingly apparent is the need to move the needle forward in the treatment of NSCLC and we will discuss the challenges associated with the current therapeutic landscape and the emerging checkpoints and the future directions that are being explored in the management of metastatic NSCLC.